{"id":592426,"date":"2022-03-22T20:57:02","date_gmt":"2022-03-22T20:57:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=592426"},"modified":"2022-03-22T20:57:02","modified_gmt":"2022-03-22T20:57:02","slug":"psoriatic-arthritis-market-analysis-of-epidemiology-pipeline-products-and-key-companies-working-in-the-segment","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/psoriatic-arthritis-market-analysis-of-epidemiology-pipeline-products-and-key-companies-working-in-the-segment_592426.html","title":{"rendered":"Psoriatic Arthritis Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working in the Segment"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1647859057.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Psoriatic Arthritis Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working in the Segment\" src=\"https:\/\/www.abnewswire.com\/uploads\/1647859057.jpeg\" alt=\"Psoriatic Arthritis Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working in the Segment\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Psoriatic Arthritis Market<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Psoriatic Arthritis Market Insights, Epidemiology, and Market Forecast-2032&#8221; report delivers an in-depth understanding of the Psoriatic Arthritis, historical and forecasted epidemiology as well as the Psoriatic Arthritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\"><strong>DelveInsight has launched a new report on <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/psoriatic-arthritis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">&#8220;Psoriatic Arthritis &#8211; Market Insights, Epidemiology, and Market Forecast-2030&rdquo;.<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s &ldquo;Psoriatic Arthritis &ndash; Market Insights, Epidemiology, and Market Forecast-2030&Prime; report delivers an in-depth understanding of the Psoriatic Arthritis, historical and forecasted epidemiology as well as the Psoriatic Arthritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/psoriatic-arthritis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Psoriatic Arthritis Market Report:<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The prevalence of PsA among the in large population-based medical records database in the UK (The Health Improvement Network) was 0.19% (95% CI 0.185%, 0.193%) and among patients with confirmed psoriasis was 8.6% (95% CI 7.7%, 9.5%) (Ogdie et al., 2013)<\/li>\n<li>According to study by P&eacute;rez et., al (2020), the prevalence of PsA in Spain was among the highest reported to date, only below that reported in Norway (0.67%) and slightly higher than that reported in Italy (0.42%).<\/li>\n<li>PsA was identified in 431 of 3021 patients with psoriasis, with a mean prevalence of 14.3% (range, 8.8&ndash;20.4%)&nbsp; in Japan(Ohara, et., al&nbsp; 2015)<\/li>\n<li>According to a retrospective study of German healthcare insurance data, PsA had prevalence rates of 0.3% respectively, in 2016 (Grellmann et al., 2020).<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Key benefits of the report:<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>Psoriatic Arthritis market report covers a descriptive overview and comprehensive insight of the Psoriatic Arthritis Epidemiology and Psoriatic Arthritis&nbsp; market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) &amp; Japan.)<\/li>\n<li>The Psoriatic Arthritis market report provides insights on the current and emerging therapies.<\/li>\n<li>Psoriatic Arthritis market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/li>\n<li>The Psoriatic Arthritis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Psoriatic Arthritis market.<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>Psoriatic Arthritis Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory rheumatic disease characterized by pain, stiffness, swollen joints, joint erosion, and bone formation. Clinical manifestations vary greatly between patients. It can present with oligoarticular joint involvement that is typically asymmetric or as a polyarticular disease affecting five or more joints, usually with asymmetric distribution similar to that of rheumatoid arthritis.<\/p>\n<p style=\"text-align: justify;\"><strong>Psoriatic Arthritis Market&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>The dynamics of the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/psoriatic-arthritis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Psoriatic Arthritis market<\/a> is anticipated to change in the coming years owing to the expected launch of emerging therapies such as AbbVie, Sun Pharma, Bristol-Myers Squibb, AbbVie, UCB Biopharma, Pfizer, and others during the forecasted period 2018-2030.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Psoriatic Arthritis Pipeline Therapies and Key Companies&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Skyrizi: AbbVie<\/li>\n<li>Ilumya: Sun Pharma<\/li>\n<li>Deucravacitinib: Bristol-Myers Squibb<\/li>\n<li>Rinvoq: AbbVie<\/li>\n<li>Bimekizumab: UCB Biopharma<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Psoriatic Arthritis Market Drivers&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Development of Animal Models<\/li>\n<li>Research and Development<\/li>\n<li>Integration of multidisciplinary treatment approach<\/li>\n<li>Technological Advancements<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis<\/p>\n<p style=\"text-align: justify;\">4. Psoriatic Arthritis Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Psoriatic Arthritis Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Psoriatic Arthritis Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Psoriatic Arthritis Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Psoriatic Arthritis&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Psoriatic Arthritis Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Psoriatic Arthritis Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Psoriatic Arthritis Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Psoriatic Arthritis Market Analysis (2018&ndash;2030)<\/p>\n<p style=\"text-align: justify;\">14. Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Market drivers<\/p>\n<p style=\"text-align: justify;\">16. Market barriers<\/p>\n<p style=\"text-align: justify;\">17. Appendix<\/p>\n<p style=\"text-align: justify;\">18. Psoriatic Arthritis Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\"><strong>Related Reports:<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/psoriatic-arthritis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Psoriatic Arthritis Pipeline&nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&#8220;Psoriatic Arthritis Pipeline Insight, 2021&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Psoriatic Arthritis market. A detailed picture of the Psoriatic Arthritis pipeline landscape is provided, which includes the disease overview and Psoriatic Arthritis treatment guidelines.<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/psoriatic-arthritis-epidemiology-forecast?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Psoriatic Arthritis Epidemiology<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8216;Psoriatic Arthritis&nbsp; Epidemiology Forecast to 2030&#8217; report delivers an in-depth understanding of the disease, historical and forecasted Psoriatic Arthritis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=psoriatic-arthritis-market-analysis-of-epidemiology-pipeline-products-and-key-companies-working-in-the-segment\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=psoriatic-arthritis-market-analysis-of-epidemiology-pipeline-products-and-key-companies-working-in-the-segment\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Psoriatic Arthritis Market DelveInsight&#8217;s &#8220;Psoriatic Arthritis Market Insights, Epidemiology, and Market Forecast-2032&#8221; report delivers an in-depth understanding of the Psoriatic Arthritis, historical and forecasted epidemiology as well as the Psoriatic Arthritis market trends in the United States, EU5 (Germany, Spain, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/psoriatic-arthritis-market-analysis-of-epidemiology-pipeline-products-and-key-companies-working-in-the-segment_592426.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,413,404],"tags":[],"class_list":["post-592426","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Services","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/592426","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=592426"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/592426\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=592426"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=592426"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=592426"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}